Elraglusib induces cytotoxicity via direct microtubule destabilization independently of GSK3 inhibition
JT Coats, S Li, TU Tanaka, S Tauro… - Cancer Research …, 2024 - aacrjournals.org
Abstract Elraglusib (9-ING-41) is an ATP-competitive inhibitor of glycogen synthase kinase-3
(GSK3) with preclinical studies demonstrating broad activity against many tumor types …
(GSK3) with preclinical studies demonstrating broad activity against many tumor types …